FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the


DARMSTADT, Germany and NEW YORK, February 11, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media Merck and Pfizer Inc. today announced that ... Lees verder

Bron: ANP Pers support
Geplaatst: 11 feb 2019 - 23:55